Biotech and Pharmaceuticals Under Siege: What the Data Actually Shows About Cyber Risk in Life Sciences

I've spent more than 40 years in information technology. And I'll be honest, the threat landscape I'm watching right now in life sciences is unlike anything I've seen before. Not because attacks are new, but because the scale, the sophistication, and the consequences are compounding faster than most organizations are prepared for.

This isn't a sales pitch. It's a look at what the research and real-world incidents are telling us, and what I think it means.

The Numbers Don't Lie: Life Sciences Is the Highest-Value Target

The pharmaceutical and biotech sector has become, by multiple independent measures, one of the most attacked industries on the planet.

According to the IBM Cost of a Data Breach Report 2025, pharmaceutical data breaches now carry an average cost of $4.61 million per incident — among the highest of any industry. That figure covers forensic investigation, system recovery, regulatory penalties, and reputational fallout, but it doesn't fully capture the cost of stolen intellectual property, which is often impossible to quantify.

The scale of breach activity tells its own story. Research tracking the 14 largest data breaches between 2020 and 2025 found that 7 of those 14 occurred within the pharmaceutical industry. The 2024 Change Healthcare breach alone compromised the records of 190 million people — up from 45.9 million records compromised across all of healthcare in 2021. The trend line is steep and it is moving in the wrong direction.

Ransomware is currently the single largest threat vector, accounting for 29.1% of all attacks on the sector, with data breaches close behind at 26.7%. The broader healthcare sector — which includes pharmaceuticals — is now ranked as the fourth most-targeted industry globally for ransomware, with a 4.8% increase in incidents compared to 2024.

Real Incidents, Real Consequences

These aren't abstract statistics. The incidents happening right now have real operational impact.

In August 2025, Inotiv — a U.S.-based contract research organization serving pharmaceutical and biotech clients — disclosed a ransomware attack by the Qilin group that encrypted portions of its network and forced operations offline. Attackers claimed to have exfiltrated approximately 170 GB of sensitive data, including files linked to drug development and client research. Inotiv filed an SEC disclosure and engaged third-party forensic experts, but had no confirmed recovery timeline at the time of reporting.

That same month, a threat actor on the XSS forum claimed to be selling unauthorized network access to a UK-based pharmaceutical and biotech manufacturer with $3.3 billion in revenue — one of dozens of credential and access sales targeting the sector recorded by the CybelAngel REACT team in 2025 alone.

In May 2026, West Pharmaceutical Services — a supplier of injectable packaging and drug delivery systems used widely across the healthcare supply chain — disclosed a material ransomware attack in an SEC filing. Attackers exfiltrated data and encrypted systems, prompting the company to shut down portions of its infrastructure. The company engaged Palo Alto Networks Unit 42 for incident response. Full recovery timelines remained unclear at the time of disclosure.

These are not edge cases. They represent a pattern of sustained, targeted attacks on organizations whose products and data underpin the broader healthcare system.

Why Employees Remain the Primary Entry Point

Technical vulnerabilities matter, but the data consistently shows that human risk is the dominant attack vector in this sector. Phishing emails impersonating vendors, IT departments, shipping carriers, and regulatory bodies are growing harder to distinguish from legitimate communication — and attackers are continuously refining their approach.

Industry phishing simulation data puts average click rates across life sciences and manufacturing organizations at 25–35%. To put that in context: in an organization of 200 employees, that's potentially 50–70 people who would interact with a malicious email before any technical control catches it.

Research across healthcare and pharma also finds that 87% of companies report being negatively affected by a breach originating in their third-party ecosystem — vendors, suppliers, CROs, and logistics partners whose systems are connected to yours but outside your direct control. This is the supply chain risk that is now a formal requirement under NIST CSF 2.0, and it represents one of the most underprepared areas for mid-size life sciences organizations.

Additionally, 73% of healthcare and pharmaceutical organizations are running legacy systems that lack native support for modern detection and monitoring tools — creating blind spots that are difficult and expensive to close with in-house resources alone.

What This Means for How You Think About Security

The threat environment in life sciences is no longer a single adversary type or a single attack method. It is, as recent research describes it, a hybrid threat environment where financially motivated ransomware groups, state-sponsored espionage operators, and opportunistic credential brokers converge on the same targets — because the value of what you hold justifies the investment from all of them.

Perimeter defense alone is insufficient. A firewall doesn't stop a phishing email. Endpoint tools don't compensate for unmonitored cloud environments. And annual security training doesn't change employee behavior in the moment a sophisticated spear-phishing email lands in their inbox.

What does work — consistently, across organizations of varying size and sophistication — is continuous monitoring, behavioral detection, and rapid response capability: knowing what normal looks like in your environment so that anomalies surface immediately, and having the people and processes in place to act on them before damage compounds.

For most mid-size biotech and pharma organizations, the practical path to that capability is a managed security operations model. Building and staffing a 24/7 internal SOC requires significant investment in tooling, talent, and ongoing training that most organizations cannot sustain — particularly given the current shortage of qualified cybersecurity professionals.

A Starting Point: Assess Before You Assume

One of the most common things I hear from life sciences leaders is that they believe their current posture is "probably fine." The research — and the incidents — suggest that assumption carries significant risk.

A dark web scan and external attack surface review will frequently reveal exposed credentials, misconfigured systems, and publicly visible assets that internal teams aren't aware of. A phishing simulation run against your own team will give you an honest picture of where human risk actually sits — not where you hope it sits.

Neither assessment requires significant time or disruption. But both will give you something more valuable than assumptions: accurate information about where you actually stand.

That's why we're offering two complimentary assessments for life sciences organizations:

Cyber Exposure Summary — a report combining a dark web scan with an external attack surface review of your internet-facing systems. No cost, no commitment. Just an honest picture of your current exposure. Contact us to schedule

Phishing Simulation — a single realistic test campaign run against your team, with no disruption to operations. We walk you through the results: what was clicked, by whom, and what it means for your organization. Contact us to schedule

No lengthy procurement process. No big commitment. Just accurate, actionable information so you can make better decisions. Contact us to schedule.